U.S., March 26 -- ClinicalTrials.gov registry received information related to the study (NCT06893016) titled 'Evaluation of RAY1225 in Adult Participants Who Have Obesity or Are Overweight' on March 18.
Brief Summary: The primary objective of this study is to demonstrate that RAY1225 is superior to placebo for percent change in body weight.
Study Start Date: June 15, 2025
Study Type: INTERVENTIONAL
Condition:
Obesity
Intervention:
DRUG: RAY1225
RAY1225 will be administered SC
DRUG: Placebo
Placebo will be administered SC.
Recruitment Status: NOT_YET_RECRUITING
Sponsor: Guangdong Raynovent Biotech Co., Ltd
Published by HT Digital Content Services with permission from Health Daily Digest....